难治性白塞病葡萄膜炎患者阿达木单抗治疗成功优化
这项开放标签多中心研究评估了74例常规免疫抑制剂难治的白塞病葡萄膜炎患者中,65例经阿达木单抗中位6个月达缓解后,23例(35.4%)优化治疗(延长给药间隔),42例维持40mg/皮下/2周。优化组与非优化组眼部结局相似,但相关不良事件仅见于非优化组,且优化组年均费用更低(6101.25欧元 vs 12339.48,P<0.01)。作者认为优化治疗有效、安全且经济。
要点
- 23例(35.4%)白塞病葡萄膜炎患者达缓解后优化阿达木单抗治疗(延长给药间隔)。
- 优化组与非优化组主要眼部结局相似,相关不良事件仅见于非优化组。
- 优化组年均费用低于非优化组:6101.25欧元 vs 12339.48(P<0.01)。
核心结论
- 对常规治疗难治的白塞病葡萄膜炎,优化阿达木单抗治疗是有效、安全且经济的。
研究设计与样本
- 开放标签多中心研究,纳入74例常规免疫抑制剂难治的白塞病葡萄膜炎患者,其中65例经阿达木单抗中位6个月(范围3-12个月)达缓解。
- 23例(35.4%)在患者与主治医生共同决策下优化治疗(逐步延长给药间隔),其余42例维持阿达木单抗40mg皮下注射每2周。
主要发现
- 优化组与非优化组在阿达木单抗起始时无人口学或眼部差异。
- 优化组和非优化组平均随访分别为34.7±13.3个月和26±21.3个月,大多数眼部结局相似。
- 相关不良事件仅见于非优化组:淋巴瘤、肺炎、注射部位严重局部反应和大肠埃希菌菌血症各1例。
- 优化组平均阿达木单抗治疗费用低于非优化组:每患者每年6101.25欧元 vs 12339.48欧元(P<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess efficacy, safety, and cost-effectiveness of adalimumab (ADA) therapy optimization in a large series of patients with uveitis due to Behçet disease (BD) who achieved remission after the use of this biologic agent. DESIGN: Open-label multicenter study of ADA-treated patients with BD uveitis refractory to conventional immunosuppressants. SUBJECTS: Sixty-five of 74 patients with uveitis due to BD, who achieved remission after a median ADA duration of 6 (range, 3-12) months. ADA was optimized in 23 (35.4%) of them. This biologic agent was maintained at a dose of 40 mg/subcutaneously/2 weeks in the remaining 42 patients. METHODS: After remission, based on a shared decision between the patient and the treating physician, ADA was optimized. When agreement between patient and physician was reached, optimization was performed by prolonging the ADA dosing interval progressively. Comparison between optimized and nonoptimized patients was performed. MAIN OUTCOME MEASURES: Efficacy, safety, and cost-effectiveness in optimized and nonoptimized groups. To determine efficacy, intraocular inflammation (anterior chamber cells, vitritis, and retinal vasculitis), macular thickness, visual acuity, and the sparing effect of glucocorticoids were assessed. RESULTS: No demographic or ocular differences were found at the time of ADA onset between the optimized and the nonoptimized groups. Most ocular outcomes were similar after a mean ± standard deviation follow-up of 34.7±13.3 and 26±21.3 months in the optimized and nonoptimized groups, respectively. However, relevant adverse effects were only seen in the nonoptimized group (lymphoma, pneumonia, severe local reaction at the injection site, and bacteremia by Escherichia coli, 1 each). Moreover, the mean ADA treatment costs were lower in the optimized group than in the nonoptimized group (6101.25 euros/patient/year vs. 12 339.48; P < 0.01). CONCLUSION: ADA optimization in BD uveitis refractory to conventional therapy is effective, safe, and cost-effective.
引用
- Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. Ophthalmology. 2018. PMID: 29602570. doi:10.1016/j.ophtha.2018.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。